Charnwood Molecular acquires Aurelia Bioscience

June 2021

Download Press Release

Synova portfolio company, Charnwood Molecular, a leading UK-based pre-clinical discovery CRO servicing the global pharmaceutical and biotechnology market, is pleased to announce the acquisition of biosciences specialist, Aurelia Bioscience.

The sector-leading expertise and technology development within Aurelia Bioscience will further expand Charnwood’s capabilities in the provision of world-class integrated drug discovery and development services. Charnwood is already a leading provider of medicinal and scale-up chemical development to the life sciences industry with a global customer base from biotech to large pharma. Aurelia will bring biology capabilities into the group allowing it to deliver holistic, integrated pre-clinical drug discovery programmes for its clients.

This acquisition follows the announcement in April this year when Charnwood committed to quadrupling its physical capacity through investment in state-of-the-art facilities at the Charnwood Campus Science Innovation and Technology Park in Loughborough. These market-leading laboratories will provide a gold-standard platform, enhancing the combined group’s ability to deliver exceptional services to its clients and supporting further growth in Charnwood’s team and capabilities.

CEO of Charnwood Molecular, Steve Allin, commented:

We are proud to welcome the Aurelia Bioscience team into our company. Gary Allenby, Kathy Dodgson and their team have built an enviable reputation for scientific rigour and excellence - values that are deeply rooted in our own business culture - and this acquisition represents another key piece in our strategic plan to become the provider of choice for integrated drug discovery and development services within the global life sciences sector.”

Zac Tsai, Partner at Synova and Director of Charnwood Molecular, noted:

“The acquisition of Aurelia represents another exciting milestone in Charnwood Molecular’s journey and Synova continues to support the team’s ambitious strategy of scale and service line expansion through a combination of organic investment and M&A.”